Guardant Health partners with The Royal Marsden NHS Foundation for TRACC study

Guardant Health is partnering with The Royal Marsden NHS Foundation Trust on Part C of its "Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer," TRACC, study, which will evaluate the use of circulating tumor DNA, ctDNA, to guide chemotherapy treatment decisions after curative-intent surgery in patients with early-stage colorectal cancer, CRC. The trial is intended to determine whether patients can be spared unnecessary chemotherapy and the associated side effects if they test negative for ctDNA using the Guardant Reveal blood test following surgery. The study will use the Guardant Reveal blood test to detect MRD by measuring the DNA shed from tumor cells into the bloodstream. Global studies have shown that a negative ctDNA result after surgery is associated with a significantly lower likelihood of the cancer returning. The TRACC Part C trial aims to evaluate the use of ctDNA results from the Guardant Reveal test to guide chemotherapy treatment decisions in a multi-center, prospective, randomized study over the next four years. "With the Guardant Reveal test, a simple blood draw can be used to identify colorectal cancer patients who have residual disease and are most likely to benefit from adjuvant therapy," said Helmy Eltoukhy, Guardant Health co-CEO. "We’re pleased to partner with The Royal Marsden in the TRACC Part C study to enable the investigators to more accurately predict when cancer is unlikely to return, help guide chemotherapy treatment decisions and provide patients with a better quality of life."